Palisade Bio Inc (PALI) Stock Analysis

Palisade Bio Inc (PALI) is a publicly traded company in the HEALTHCARE sector. It trades at $1.86, carries a market capitalization of $368.41M, a price-to-earnings ratio of 17.67. This page summarizes the public market data, fundamentals, and frequently asked questions for PALI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Palisade Bio Inc currently has a Neutral sentiment score of 0.14.

About Palisade Bio Inc

Palisade Bio Inc. is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, specializing in the development of innovative therapies aimed at protecting the gastrointestinal mucosal barrier. The company's proprietary drug candidates target significant unmet medical needs in gastrointestinal disorders, reflecting a commitment to improving patient outcomes. With a robust research and development framework, Palisade Bio is strategically positioned to advance the field o...

GNG Research Analysis

GNG Research scores Palisade Bio Inc (PALI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PALI.

Frequently Asked Questions

Does PALI pay dividends?

Palisade Bio Inc (PALI) does not currently pay a regular dividend.

What is PALI's P/E ratio?

Palisade Bio Inc has a price-to-earnings (P/E) ratio of 17.67.

What is PALI's market cap?

Palisade Bio Inc (PALI) has a market capitalization of $368.41M with a current stock price of $1.86.